title: A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
abstract: BACKGROUND
  Although antidepressants are the pharmacological agents most often studied in the treatment of binge-eating disorder (BED), preliminary evidence from an open trial suggests that the antiobesity agent sibutramine hydrochloride may be effective. The objective of this study was to evaluate the efficacy and tolerability of sibutramine in obese patients with BED.
  
  
  METHODS
  After a 2-week run-in period, 60 obese outpatients (body mass index [calculated as weight in kilograms divided by the square of height in meters] 30-45), who met DSM-IV criteria for BED were randomly assigned to receive sibutramine hydrochloride (n = 30), 15 mg/d, or placebo (n = 30) in a 12-week double-blind study at 2 centers. The primary outcome measure was binge frequency, expressed as the number of days with binge-eating episodes during the past week. Secondary outcome measures included Binge Eating Scale, Beck Depression Inventory scores, weight, and treatment responder status (remission and response). For each efficacy outcome, an intent-to-treat analysis was performed using random regression methods.
  
  
  RESULTS
  There was a significant reduction in the number of days with binge episodes in the sibutramine group compared with the placebo group (t203 = 2.14; P =.03); this was associated with an important and significant weight loss (-7.4 kg) compared with a small weight gain in the placebo group (1.4 kg) (t147 = 4.88; P<.001). Sibutramine was also associated with a significantly greater rate of reduction in Binge Eating Scale (t202 = 3.64; P<.001) and Beck Depression Inventory (t201 = 3.72; P<.001) scores. Dry mouth (P =.01) and constipation (P<.001) were more common adverse reactions with sibutramine than placebo.
  
  
  CONCLUSIONS
  Sibutramine is effective and well tolerated in the treatment of obese patients with BED. Its effects address 3 main domains of the BED syndrome, ie, binge eating, weight, and related depressive symptoms.
authors: Obesity and Eating Disorders Group, Institute of Psychiatry, Federal University of Rio de Janeiro, Rua Visconde de Pirajá 550/2002-Ipanema, Rio de Janeiro, Brazil 22410-001. appolinario@biohard.com.br
authors: Jose C
authors: JC
authors: Appolinario
authors: Josué
authors: J
authors: Bacaltchuk
authors: Rosely
authors: R
authors: Sichieri
authors: Angelica M
authors: AM
authors: Claudino
authors: Amelio
authors: A
authors: Godoy-Matos
authors: Christina
authors: C
authors: Morgan
authors: Maria T
authors: MT
authors: Zanella
authors: Walmir
authors: W
authors: Coutinho
mesh_terms: D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002032:Bulimia / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003503:Cyclobutanes / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D010555:Personality Inventory; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine